Literature DB >> 23917722

Highlights of the 25th Anniversary EANM Congress Milan 2012: nuclear medicine and molecular imaging at its best.

Werner Langsteger1, Mohsen Beheshti.   

Abstract

The European Association of Nuclear Medicine (EANM) celebrated its 25th Anniversary Congress in Milan under the chairmanship of Professor Emilio Bombardieri and the auspices of the Italian Society of Nuclear Medicine. As always, the Congress was a great success: more than 5,530 participants from 88 countries came from Europe and beyond. In spite of limited budgets, industry again made an important contribution: New innovative equipment and tracers demonstrating the latest technology and innovations were presented by 122 companies. This review is a brief summary of the major scientific contributions made in the fields of oncology, multimodality imaging, cardiovascular science, neurology and psychiatry, technological innovation and novel tracers, and in other clinical sciences as well as in radionuclide therapy, which all show promising and great innovations.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23917722     DOI： 10.1007/s00259-013-2517-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


  18 in total

1.  For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic heart failure? Results of a pooled individual patient data meta-analysis.

Authors:  Derk O Verschure; Caroline E Veltman; Alain Manrique; G Aernout Somsen; Maria Koutelou; Athanasios Katsikis; Denis Agostini; Myron C Gerson; Berthe L F van Eck-Smit; Arthur J H A Scholte; Arnold F Jacobson; Hein J Verberne
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-03-30       Impact factor: 6.875

2.  Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer.

Authors:  Michael Souvatzoglou; Matthias Eiber; Toshiki Takei; Sebastian Fürst; Tobias Maurer; Florian Gaertner; Hans Geinitz; Alexander Drzezga; Sibylle Ziegler; Stephan G Nekolla; Ernst J Rummeny; Markus Schwaiger; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-02       Impact factor: 9.236

3.  89Zr-bevacizumab PET imaging in primary breast cancer.

Authors:  Sietske B M Gaykema; Adrienne H Brouwers; Marjolijn N Lub-de Hooge; Rick G Pleijhuis; Hetty Timmer-Bosscha; Linda Pot; Gooitzen M van Dam; Sibylle B van der Meulen; Johan R de Jong; Joost Bart; Jakob de Vries; Liesbeth Jansen; Elisabeth G E de Vries; Carolien P Schröder
Journal:  J Nucl Med       Date:  2013-05-07       Impact factor: 10.057

4.  Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.

Authors:  Linda Villard; Anna Romer; Nicolas Marincek; Philippe Brunner; Michael T Koller; Christian Schindler; Quinn K T Ng; Helmut R Mäcke; Jan Müller-Brand; Christoph Rochlitz; Matthias Briel; Martin A Walter
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

5.  (18)F-fluoride PET/CT in avascular necrosis of the femoral head.

Authors:  Shankaramurthy Gayana; Anish Bhattacharya; Raghava Kashyap; Ramesh Kumar Sen; Bhagwant Rai Mittal
Journal:  Clin Nucl Med       Date:  2013-06       Impact factor: 7.794

6.  Laparoscopic sentinel lymph node (SLN) versus extensive pelvic dissection for clinically localized prostate carcinoma.

Authors:  Caroline Rousseau; Thierry Rousseau; Boumédiène Bridji; Amandine Pallardy; Jacques Lacoste; Loïc Campion; Aude Testard; Geneviève Aillet; Ayat Mouaden; Chantal Curtet; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-16       Impact factor: 9.236

7.  In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene.

Authors:  Hao Hong; Kai Yang; Yin Zhang; Jonathan W Engle; Liangzhu Feng; Yunan Yang; Tapas R Nayak; Shreya Goel; Jero Bean; Charles P Theuer; Todd E Barnhart; Zhuang Liu; Weibo Cai
Journal:  ACS Nano       Date:  2012-02-16       Impact factor: 15.881

8.  Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.

Authors:  C Pettinato; F Monari; C Nanni; V Allegri; S Marcatili; S Civollani; S Cima; E Spezi; R Mazzarotto; S Fanti
Journal:  Q J Nucl Med Mol Imaging       Date:  2012-12       Impact factor: 2.346

9.  Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study.

Authors:  Maarten L J Smits; Johannes F W Nijsen; Maurice A A J van den Bosch; Marnix G E H Lam; Maarten A D Vente; Willem P T M Mali; Alfred D van Het Schip; Bernard A Zonnenberg
Journal:  Lancet Oncol       Date:  2012-08-22       Impact factor: 41.316

10.  Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas.

Authors:  Flavio Forrer; Catharina Oechslin-Oberholzer; Benedetta Campana; Richard Herrmann; Helmut R Maecke; Jan Mueller-Brand; Andreas Lohri
Journal:  J Nucl Med       Date:  2013-04-09       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.